Vivo Capital
DYN icon

Vivo Capital’s Dyne Therapeutics DYN Stock Holding History

Vivo Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.29M Sell
514,402
-1,043,064
-67% -$24M 0.91% 30
2026
Q2 		$34.6M Hold
1,557,466
– – 3.16% 12
2026
Q1 		$28.2M Sell
1,557,466
-1,057,494
-40% -$18.2M 2.35% 13
2025
Q4 		$51.1M Hold
2,614,960
– – 3.31% 8
2025
Q3 		$33.1M Buy
2,614,960
+1,500,000
+135% +$17.1M 2.66% 12
2025
Q2 		$10.6M Hold
1,114,960
– – 1.09% 16
2025
Q1 		$11.7M Hold
1,114,960
– – 1.54% 10
2024
Q4 		$26.3M Hold
1,114,960
– – 2.94% 6
2024
Q3 		$40M Sell
1,114,960
-520,176
-32% -$20.7M 3.31% 8
2024
Q2 		$57.7M Hold
1,635,136
– – 5.33% 5
2024
Q1 		$46.4M Buy
1,635,136
+600,000
+58% +$13.6M 3.65% 8
2023
Q4 		$13.8M Hold
1,035,136
– – 1.13% 17
2023
Q3 		$9.27M Buy
1,035,136
+457,494
+79% +$4.93M 1.02% 25
2023
Q2 		$6.5M Hold
577,642
– – 0.45% 31
2023
Q1 		$6.65M Hold
577,642
– – 0.46% 28
2022
Q4 		$6.7M Hold
577,642
– – 0.77% 28
2022
Q3 		$7.34M Hold
577,642
– – 0.81% 32
2022
Q2 		$3.97M Hold
577,642
– – 0.4% 42
2022
Q1 		$5.57M Hold
577,642
– – 0.38% 42
2021
Q4 		$6.87M Hold
577,642
– – 0.41% 42
2021
Q3 		$9.38M Hold
577,642
– – 0.42% 40
2021
Q2 		$12.2M Hold
577,642
– – 0.53% 35
2021
Q1 		$8.97M Buy
577,642
+262,642
+83% +$5.08M 0.32% 45
2020
Q4 		$6.62M Hold
315,000
– – 0.3% 47
2020
Q3 		$6.36M Buy
+315,000
New +$6.91M 0.37% 48

Other funds holding DYN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Vivo Capital's DYN Position: Q3 2026 in Review

Vivo Capital reduced its Dyne Therapeutics (DYN) stake by 67% in Q3 2026, selling an estimated $24M and leaving 514,402 shares worth $8.29M. The position accounts for 0.91% of the portfolio, ranked #30.

Vivo Capital first reported a position in DYN in Q3 2020 and has held it in 25 quarters since. The position peaked at $57.7M in Q2 2024. 167 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

  • Vivo Capital held 514,402 shares of Dyne Therapeutics worth $8.29M as of Q3 2026.
  • Vivo Capital sold 1,043,064 Dyne Therapeutics shares in Q3 2026, an estimated $24M.
  • Dyne Therapeutics made up 0.91% of Vivo Capital's portfolio in Q3 2026, its #30 holding.
  • Vivo Capital first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 25 quarters since.
  • Vivo Capital's Dyne Therapeutics position peaked at $57.7M in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on Vivo Capital's 13F filing for Q3 2026, filed 13 Nov 2026.